Moteur de recherche d’entreprises européennes
UK funding (579 056 £) : Comprendre et prédire l’agrégation dans les produits biopharmaceutiques Ukri01/11/2011 UK Research and Innovation, Royaume Uni
Vue d’ensemble
Texte
Comprendre et prédire l’agrégation dans les produits biopharmaceutiques
| Abstract | Currently, one of the bottle necks to developing cheaper protein therapeutics is the cost of the downstream bioprocessing and formulation steps. A key problem is the loss of active protein therapeutic to irreversible aggregation throughout the bioprocess. Other problems can arise during chromatography or filtration when encountering high protein concentrations which could lead to high viscosites or even precipitation. The focus of this work is to develop predictive methods for identifying problematic conditions early on in the bioprocess. These could then be used for identifying changes to the protein to minimize the problems. Alternatively, the method could be used for optimizing the solvent properties (pH, buffer type and concentration) or finding other small molecule additives to be used in order to avoid aggregation or increase protein solubility. We benchmark our approach by studying antibodies and antibody fragments due to their growing importance as human therapeutics. |
| Category | Research Grant |
| Reference | BB/I017194/1 |
| Status | Closed |
| Funded period start | 01/11/2011 |
| Funded period end | 30/11/2014 |
| Funded value | £579 056,00 |
| Source | https://gtr.ukri.org/projects?ref=BB%2FI017194%2F1 |
Participating Organisations
| The University of Manchester | |
| EPSRC | |
| AstraZeneca | |
| Lund University | |
| University of Copenhagen | |
| Technical University of Denmark | |
| Wyatt Technology Corporation | |
| Novozymes | |
| Albumedix Ltd | |
| Ludwig Maximilian University of Munich (LMU Munich) |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : The University of Manchester, Manchester, Royaume Uni.
Les visualisations de "The University of Manchester - UK funding (579 056 £) : Comprendre et prédire l’agrégation dans les produits biopharmaceutiques"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
